

10/593,801

=> file caplus

FILE 'CAPLUS' ENTERED AT 10:53:33 ON 29 NOV 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2010 VOL 153 ISS 23

FILE LAST UPDATED: 28 Nov 2010 (20101128/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2010

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:


<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que

L1

STR



Structure attributes must be viewed using STN Express query preparation.

L3 207 SEA FILE=REGISTRY SSS FUL L1

L4 3 SEA FILE=CAPLUS L3

=> d l4 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1590347 CAPLUS

DOCUMENT NUMBER: 152:230142


TITLE: Discovery of orally available integrin $\alpha 5\beta 1$ antagonists

AUTHOR(S): Zischinsky, Gunther; Osterkamp, Frank; Vossmeier, Doerte; Zahn, Grit; Scharn, Dirk; Zwintscher, Ariane; Stragies, Roland

CORPORATE SOURCE: Jerini AG, Berlin, D-10115, Germany

10/593,801

SOURCE: Bioorganic & Medicinal Chemistry Letters (2010),
20(1), 380-382
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 152:230142
GI



I

AB Previous research within our labs. identified the 3-hydroxypyrrolidine scaffold 1 (I) as a new and selective integrin $\alpha 5 \beta 1$ inhibitor class which was designed for local administration. Herein the discovery of new orally available integrin $\alpha 5 \beta 1$ inhibitor scaffolds for potential systemic treatment is described.


IT 865436-62-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discovery of orally available integrin $\alpha 5 \beta 1$ antagonists)

RN 865436-62-0 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-(2,4,6-trimethylbenzoyl)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:749853 CAPLUS

DOCUMENT NUMBER: 147:335593

TITLE: Design and Synthesis of a New Class of Selective Integrin $\alpha 5 \beta 1$ Antagonists

AUTHOR(S): Stragies, Roland; Osterkamp, Frank; Zischinsky, Gunther; Vossmeier, Doerte; Kalkhof, Holger; Reimer, Ulf; Zahn, Grit

CORPORATE SOURCE: Jerini AG, Berlin, D-10115, Germany

SOURCE: Journal of Medicinal Chemistry (2007), 50(16), 3786-3794

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:335593

GI



I

AB Nonracemic [(pyridinemethylamino)pyrrolidinyloxy]acetyl α, β -diamino acids such as I are prepared as integrin $\alpha 5 \beta 1$ antagonists; their inhibition of integrin $\alpha 5 \beta 1$ and their selectivities for integrin $\alpha 5 \beta 1$ over integrins $\alpha v \beta 3$, $\alpha v \beta 5$, $\alpha IIb \beta 3$, and $\alpha 3 \beta 1$ are determined. The selectivity of the [(pyridinemethylamino)pyrrolidinyloxy]acetyl α, β -diamino acid inhibitors for integrins is improved by replacing an N-mesitylsulfonyl group at the α -amino acid moiety with a N-mesitylcarbonyl group.

IT 865436-01-7P 865436-04-0P 865436-62-0P
865436-67-5P 865436-68-6P 865436-72-2P
865436-73-3P 865437-07-6P 865437-52-1P
865437-53-2P 865437-54-3P 865437-55-4P
948092-56-6P 948092-57-7P 948092-58-8P
948092-59-9P 948092-60-2P 948092-64-6P
948092-65-7P 948092-66-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of nonracemic [(pyridinemethylamino)pyrrolidinyloxy]acetyl α, β -diamino acids, their activities as integrin $\alpha 5 \beta 1$ antagonists, and their selectivities for integrin


10/593,801

receptors)
RN 865436-01-7 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 865436-00-6
CMF C32 H39 N5 O8 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 865436-04-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[(phenylsulfonyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10/593,801

RN 865436-62-0 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-(2,4,6-trimethylbenzoyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-67-5 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(1-methylcyclohexyl)carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-68-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2,4,6-trimethylbenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[[[(4-methoxy-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10/593,801

RN 865436-72-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-(benzoylamino)-2-carboxyethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-73-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[(2,4,6-trimethylbenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-07-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[(1-methylcyclohexyl)carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10/593,801

RN 865437-52-1 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[[[4-methoxy-2-pyridinyl]amino]methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-53-2 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[[[4-methoxy-2-pyridinyl]amino]methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-(2,4,6-trimethylbenzoyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-54-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[1-methylcyclohexyl]carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[[4-methoxy-2-pyridinyl]amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10/593,801

RN 865437-55-4 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[[[(4-methoxy-2-pyridinyl)amino]methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(1-methylcyclohexyl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 948092-56-6 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-methyl ester, (2S,4R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865436-55-1

CMF C26 H35 N5 O8 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




10/593,801

RN 948092-57-7 CAPLUS
CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 865436-33-5
CMF C30 H43 N5 O7 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 948092-58-8 CAPLUS
CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(1-oxo-3-phenylpropyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865436-16-4
CMF C33 H41 N5 O7 S

Absolute stereochemistry.


10/593,801



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 948092-59-9 CAPLUS


CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3-phenylpropyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyloxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865436-20-0

CMF C33 H43 N5 O6 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/593,801




RN 948092-60-2 CAPLUS
CN L-Alanine, 3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyloxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 865436-21-1
CMF C24 H33 N5 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 948092-64-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[[(4-methoxy-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865437-50-9
CMF C33 H41 N5 O9 S

Absolute stereochemistry.


10/593,801



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 948092-65-7 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[[(4-chloro-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865437-51-0

CMF C32 H38 Cl N5 O8 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/593,801



RN 948092-66-8 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[(6-methyl-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865437-44-1

CMF C33 H41 N5 O8 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1042232 CAPLUS



DOCUMENT NUMBER: 143:326206

TITLE: Preparation of trisubstituted pyrrolidine derivatives for the inhibition of angiogenesis

10/593,801

INVENTOR(S): Zahn, Grit; Stragies, Roland; Osterkamp, Frank;
Zischinsky, Gunther; Knolle, Jochen; Hummel, Gerd;
Birkner, Sascha; Reineke, Ulrich
PATENT ASSIGNEE(S): Jerini A.-G., Germany
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005090329	A1	20050929	WO 2005-EP3163	20050324
WO 2005090329	A9	20070201		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005223356	A1	20050929	AU 2005-223356	20050324
CA 2560653	A1	20050929	CA 2005-2560653	20050324
EP 1727811	A1	20061206	EP 2005-716365	20050324
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV			
CN 1938293	A	20070328	CN 2005-80009209	20050324
BR 2005009150	A	20070828	BR 2005-9150	20050324
JP 2007530491	T	20071101	JP 2007-504363	20050324
SG 151303	A1	20090430	SG 2009-1998	20050324
RU 2393154	C2	20100627	RU 2006-137367	20050324
ZA 2006006747	A	20071227	ZA 2006-6747	20060814
KR 2006128010	A	20061213	KR 2006-7018983	20060915
MX 2006010756	A	20061215	MX 2006-10756	20060920
US 20070155712	A1	20070705	US 2006-593801	20060921
IN 2006DN05533	A	20070824	IN 2006-DN5533	20060922
PRIORITY APPLN. INFO.:			EP 2004-7067	A 20040324
			WO 2005-EP3163	W 20050324
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): CASREACT 143:326206; MARPAT 143:326206				
GI				



AB Title compds. I [D = heterocyclic, homocyclic ring; X = CO, SO₂, NHCO, CONH, etc.; Y = (CH₂)₀₋₃-E-(CH₂)₀₋₃-L-(CH₂)₀₋₃, etc.; E = O, S, etc.; Q, L = CONH, CO, CS, NH, etc.; Z = CO, alkyl, CH₂, etc.; A = (un)substituted benzyl, Ph, etc.; B = CHR₁-CH(COOH)-Q-R₂; R₁₋₂ = H, (un)substituted benzyl, Ph, etc.; G = radical comprising at least one N atom] are prepared. For instance, (2S,4R)-4-carboxymethoxy-2-((pyridin-2-yl)amino)methylpyrrolidine-1-carboxylic acid benzyl ester is prepared in 4 steps from (2S,4R)-4-hydroxy-2-(carboxymethoxy)pyrrolidine-1-carboxylic acid benzyl ester, tert-Bu bromoacetate and 2-aminopyridine and further converted to II using (S)-3-amino-2-((2,4,6-trimethylbenzenesulfonyl)amino)propionic acid tert-Bu ester. II has IC₅₀ = 3.7 nM for the αvβ1 integrin receptor. I are useful in the treatment of diseases in which an inhibition of angiogenesis is desired.

IT

865436-00-6P	865436-01-7P	865436-02-8P
865436-03-9P	865436-04-0P	865436-05-1P
865436-15-3P	865436-16-4P	865436-17-5P
865436-18-6P	865436-19-7P	865436-20-0P
865436-21-1P	865436-22-2P	865436-23-3P
865436-24-4P	865436-25-5P	865436-26-6P
865436-27-7P	865436-28-8P	865436-29-9P
865436-30-2P	865436-31-3P	865436-32-4P
865436-33-5P	865436-34-6P	865436-35-7P
865436-36-8P	865436-37-9P	865436-38-0P
865436-39-1P	865436-40-4P	865436-41-5P
865436-42-6P	865436-43-7P	865436-44-8P
865436-45-9P	865436-46-0P	865436-47-1P
865436-48-2P	865436-49-3P	865436-50-6P
865436-51-7P	865436-52-8P	865436-53-9P
865436-54-0P	865436-55-1P	865436-56-2P
865436-57-3P	865436-58-4P	865436-59-5P
865436-60-8P	865436-62-0P	865436-63-1P

865436-64-2P	865436-65-3P	865436-66-4P
865436-67-5P	865436-68-6P	865436-69-7P
865436-70-0P	865436-71-1P	865436-72-2P
865436-73-3P	865436-74-4P	865436-75-5P
865436-76-6P	865436-77-7P	865436-78-8P
865436-79-9P	865436-80-2P	865436-81-3P
865436-82-4P	865436-83-5P	865436-84-6P
865436-85-7P	865436-86-8P	865436-87-9P
865436-88-0P	865436-89-1P	865436-90-4P
865436-91-5P	865436-92-6P	865436-94-8P
865436-96-0P	865436-98-2P	865437-00-9P
865437-01-0P	865437-02-1P	865437-03-2P
865437-04-3P	865437-05-4P	865437-06-5P
865437-07-6P	865437-08-7P	865437-09-8P
865437-10-1P	865437-11-2P	865437-12-3P
865437-13-4P	865437-14-5P	865437-15-6P
865437-16-7P	865437-17-8P	865437-18-9P
865437-19-0P	865437-20-3P	865437-21-4P
865437-22-5P	865437-23-6P	865437-24-7P
865437-25-8P	865437-27-0P	865437-28-1P
865437-29-2P	865437-30-5P	865437-31-6P
865437-32-7P	865437-33-8P	865437-34-9P
865437-35-0P	865437-38-3P	865437-41-8P
865437-43-0P	865437-44-1P	865437-45-2P
865437-46-3P	865437-48-5P	865437-49-6P
865437-50-9P	865437-51-0P	865437-52-1P
865437-53-2P	865437-54-3P	865437-55-4P
865437-62-3P	865437-64-5P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of trisubstituted pyrrolidine derivs. for inhibition of angiogenesis)

RN 865436-00-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-01-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

10/593,801


CRN 865436-00-6
CMF C32 H39 N5 O8 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 865436-02-8 CAPLUS
CN L-Alanine, 3-[[[(3R,5S)-1-(phenylacetyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 865436-03-9 CAPLUS
CN L-Alanine, 3-[[[(3R,5S)-1-(phenylacetyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

10/593,801


CRN 865436-02-8
CMF C32 H39 N5 O7 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 865436-04-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(phenylsulfonyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 865436-05-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(phenylsulfonyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 865436-04-0

10/593,801


CMF C29 H33 N5 O8 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 865436-15-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-butyl ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-16-4 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-(1-oxo-3-phenylpropyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-17-5 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-[(phenylmethyl)sulfonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-18-6 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-(butylsulfonyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-19-7 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-methyl-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

10/593,801


Absolute stereochemistry.



RN 865436-20-0 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-(3-phenylpropyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 865436-21-1 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 865436-22-2 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-[(cyclopentylamino)carbonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

10/593,801


Absolute stereochemistry.



RN 865436-23-3 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-[(cyclohexylamino)carbonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-24-4 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-[(butylamino)carbonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-25-5 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-[(pentylamino)carbonyl]-5-[(2-

10/593,801

pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-26-6 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-[[[(2-fluorophenyl)methyl]amino]carbonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-27-7 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-[[[(4-methylphenyl)methyl]amino]carbonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-28-8 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-[(2-phenylethyl)amino]carbonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-29-9 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-[[[(3-methylphenyl)methyl]amino]carbonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/593,801

RN 865436-30-2 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-[(phenylamino)carbonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-31-3 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-(2-methyl-1-oxopentyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-32-4 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-(3-cyclopentyl-1-oxopropyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-33-5 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-34-6 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-(cyclohexylcarbonyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-35-7 CAPLUS

10/593,801

CN L-Alanine, 3-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-1-(3,5,5-trimethyl-1-oxohexyl)-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-36-8 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-1-(2-thienylacetyl)-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-37-9 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-(cyclopentylacetyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-38-0 CAPLUS

10/593,801

CN L-Alanine, 3-[[[(3R,5S)-1-[(3-methoxyphenyl)acetyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-39-1 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-(2-methyl-1-oxopropyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-40-4 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-(1-oxopropyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-41-5 CAPLUS

10/593,801

CN L-Alanine, 3-[[[[(3R,5S)-1-(phenoxyacetyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 865436-42-6 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-benzoyl-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 865436-43-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(2-methylpropyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10/593,801

RN 865436-44-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-ethyl ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-45-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-hexyl ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-46-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(2-propyn-1-yl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10/593,801

RN 865436-47-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(3-buten-1-yl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-48-2 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-[(phenylmethyl)amino]carbonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-49-3 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-(aminocarbonyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-50-6 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-1-[[[2-(trifluoromethyl)phenyl]amino]carbonyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-51-7 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-[(1,3-benzodioxol-5-ylamino)carbonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-52-8 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-[[[1,1'-biphenyl]-4-ylamino]carbonyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-53-9 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-[[[phenylmethyl]amino]thioxomethyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-54-0 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-acetyl-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 865436-55-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-methyl ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-56-2 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-[(2-methoxyethoxy)acetyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

10/593,801


Absolute stereochemistry.



RN 865436-57-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-[(4-fluorophenyl)methyl] ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-58-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-[(4-chlorophenyl)methyl] ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-59-5 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-[3-(4-fluorophenyl)-1-oxopropyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-60-8 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-[3-(4-chlorophenyl)-1-oxopropyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-62-0 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-(2,4,6-trimethylbenzoyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-63-1 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A

HO—




PAGE 1-B



RN 865436-64-2 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-(2-anthracenylsulfonyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Me

RN 865436-65-3 CAPLUS

CN L-Alanine, 3-[[[(3R,5S)-1-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluoro-1-oxooctyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-66-4 CAPLUS

CN L-Alanine, 3-[[[[(3R,5S)-1-[3,5-bis(trifluoromethyl)benzoyl]-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-67-5 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(1-methylcyclohexyl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-68-6 CAPLUS

10/593,801

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[(2,4,6-trimethylbenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[[(4-methoxy-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-69-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-[(butylsulfonyl)amino]-2-carboxyethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-70-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[(phenylmethyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-71-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-

10/593,801

[(methylsulfonyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-72-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[2-(benzoylamino)-2-carboxyethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-73-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[2-(2,4,6-trimethylbenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-74-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[2-(phenylacetyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

10/593,801


Absolute stereochemistry.



RN 865436-75-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-[[[1,1'-biphenyl]-4-ylcarbonyl)amino]-2-carboxyethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-76-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(1-oxo-3-phenylpropyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-77-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-[[[(butylamino)carbonyl]amino]-2-carboxyethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-78-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(phenylamino)carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-79-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(phenylmethyl)amino]carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-80-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,6-dimethylphenyl)amino]carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-81-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2-phenylethyl)amino]carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-82-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-[[[1,1'-biphenyl]-4-ylamino]carbonyl]amino]-2-carboxyethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 865436-83-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-amino-2-carboxyethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)methyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

[illegible]


CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[2-(trifluoromethyl)benzoyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

O=C(O[C@H]1C[C@@H](C(=O)Nc2ccccc2)S1)OCC1=CC=CC=C1

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[3-(trifluoromethyl)benzoyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865436-87-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[4-(trifluoromethyl)benzoyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-88-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-[[3,5-bis(trifluoromethyl)benzoyl]amino]-2-carboxyethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-89-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2-methylbenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

10/593,801


Absolute stereochemistry.



RN 865436-90-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[2S]-2-carboxy-2-[(2-methoxybenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-91-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[2S]-2-carboxy-2-[(4-methylbenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-92-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[2S]-2-carboxy-2-[(2,6-dimethoxybenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

10/593,801


Absolute stereochemistry.



RN 865436-94-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[(2S)-2-carboxy-2-[(cyclohexylcarbonyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865436-96-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[(2S)-2-carboxy-2-[(2,6-dimethylbenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865436-98-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[(2S)-2-carboxy-2-[(3,5-dimethylbenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

10/593,801


Absolute stereochemistry.



RN 865437-00-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(3,4,5-trimethoxybenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-01-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2-fluorobenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.




RN	865437-02-1	CAPLUS
CN	1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[(2-nitrobenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)	

Chemical structure of compound 10: A thiazolidine ring substituted with a benzimidazole group, a benzyl ester, and a side chain containing a thioether, a carboxylic acid, and a nitrobenzamide group.

Absolute stereochemistry.



Absolute stereochemistry.




10/593,801

RN 865437-05-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[(2,6-difluorobenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-06-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[(3-methyl-2-thienyl)carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-07-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[(1-methylcyclohexyl)carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10/593,801

RN 865437-08-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(3-methyl-1-oxo-2-phenylbutyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-09-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2-ethylbenzoyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-10-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-[[[1,1'-biphenyl]-2-ylcarbonyl)amino]-2-carboxyethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865437-11-2 CAPLUS

10/593,801

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2-methylcyclohexyl)carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-12-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(1-phenylcyclopropyl)carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-13-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(1-phenylcyclopentyl)carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 865437-14-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2,2-dicyclohexylacetyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-

pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

O=C(O[C@H](C1CCCCC1)C(=O)N[C@@H](C2CCCCC2)C(=O)NCC[C@H](C(=O)O)S[C@H](C3CCCCC3)C(=O)NCC4CCCCC4)N[C@@H](C5CCCCC5)C(=O)NCC6CCCCC6)Nc7ccccc7

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[2-(dimethylamino)benzoyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

CN(C)c1ccc(cc1)C(=O)N[C@@H](C(=O)O)CNCC(=O)O[C@H]2CC[C@@H](C2N(C(=O)OCC3=CC=CC=C3)C(=N4C=CC=CC=C4)N)S

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[2-
[(difluoromethyl)thio]benzoyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-
pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Chemical structure of compound 10: A 2-phenylthio-1,3-dioxolane ring substituted with a 2-phenylthioethyl ester group at the 4-position and a 2-phenylthioethyl ester group at the 5-position. The 2-position is substituted with a 2-phenylthioethyl ester group. The 3-position is substituted with a 2-phenylthioethyl ester group.

10/593,801

RN 865437-17-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2-methyl-1-oxopentyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-18-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(3-cyclopentyl-1-oxopropyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-19-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(cyclobutylcarbonyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865437-20-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(3,3-dimethyl-1-oxobutyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

10/593,801

1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-21-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[(3,5,5-trimethyl-1-oxohexyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-22-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[(1-oxopropyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865437-23-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[(2,2-dimethyl-1-oxopropyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865437-24-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2,2-dimethyl-1-oxobutyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-25-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(cyclopropylcarbonyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865437-27-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2-cyclopentylacetyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865437-28-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2-methyl-1-oxopropyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-29-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2-cyclohexylacetyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865437-30-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(1-oxo-2-propylpentyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865437-31-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(4-methyl-1-oxopentyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-32-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(2-cycloheptylacetyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865437-33-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[2,4,6-tris(1-methylethyl)benzoyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865437-34-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(1-oxo-4-phenylbutyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-35-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[(1-oxo-5-phenylpentyl)amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865437-38-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[[(5-chloro-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 865437-41-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[[5-(trifluoromethyl)-2-pyridinyl]amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-43-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[[5-methyl-2-pyridinyl]amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865437-44-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[[6-methyl-2-pyridinyl]amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

10/593,801


Absolute stereochemistry.



RN 865437-45-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[(6-amino-2-pyridinyl)amino]methyl]-4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 865437-46-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[[(4,6-dimethyl-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

Cc1cc(C)nc(NC[C@H]2S[C@@H](COC(=O)NC[C@H](C(=O)O)SNC(=O)(=O)c3cc(C)cc(C)c3)C2)c1

1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[[(5-phenyl-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

CC1=CC=C(C=C1)C(=O)O[C@H]2C[C@@H](C[C@H]2N(C(=O)OCC1=CC=CC=C1)NC3=CC=CC=C3)OCC(=O)NC[C@H](C(=O)O)S(=O)(=O)C4=CC(=CC(=C4)C)C

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[(4-methyl-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


CC1=CC=C(C=C1)N=C2C=CC(=CC=C2)NC[C@H]3S[C@@H](COC(=O)NC[C@H](C(=O)O)NS(=O)(=O)C4=CC(=CC(=C4)C)C)N3C(=O)OCC5=CC=CC=C5

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[(2,4,6-

10/593,801

trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[(4-methoxy-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-51-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[(4-chloro-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-52-1 CAPLUS

CN L-Alanine, 3-[[2-[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[[(4-methoxy-2-pyridinyl)amino]methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




10/593,801

RN 865437-53-2 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[[[(4-methoxy-2-pyridinyl)amino]methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-(2,4,6-trimethylbenzoyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-54-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[[(2S)-2-carboxy-2-[[[(1-methylcyclohexyl)carbonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[[[(4-methoxy-2-pyridinyl)amino]methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-55-4 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-1-(3,3-dimethyl-1-oxobutyl)-5-[[[(4-methoxy-2-pyridinyl)amino]methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[(1-methylcyclohexyl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




10/593,801

RN 865437-62-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]methylamino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865437-64-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[2-[[(2R)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]-2-oxoethoxy]-2-[(2-pyridinylamino)methyl]-, 1-(phenylmethyl) ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT	1044509-15-0	1044509-17-2	1044509-21-8
	1044509-22-9	1044509-31-0	1044513-28-1
	1044513-33-8	1044513-36-1	1044513-39-4
	1044513-41-8	1044513-92-9	1044514-38-6
	1044514-86-4	1044515-32-3	1044515-50-5
	1044515-52-7	1044515-53-8	1044515-55-0
	1044515-58-3	1044515-60-7	1044515-61-8
	1044515-63-0	1044515-66-3	1044515-68-5
	1044515-77-6	1044515-78-7	1044515-84-5
	1044515-85-6	1044515-86-7	1044516-09-7
	1044516-11-1	1044516-13-3	1044516-63-3
	1044516-65-5	1044516-67-7	1044516-80-4
	1044516-81-5	1044516-82-6	1044516-84-8
	1044516-90-6	1044516-92-8	1044517-00-1
	1044517-06-7	1044517-07-8	1044517-13-6
	1044517-15-8	1044517-18-1	1044517-20-5
	1044517-21-6	1044517-37-4	1044517-40-9
	1044517-44-3	1044517-45-4	1044517-53-4
	1044517-56-7	1044517-62-5	1044517-63-6

10/593,801


1044517-64-7 1044517-84-1 1146947-94-5
1146950-65-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of trisubstituted pyrrolidine derivs. for inhibition of angiogenesis)

RN 1044509-15-0 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-(2,4,6-trimethylbenzoyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044509-17-2 CAPLUS

CN L-Alanine, N-[(1-methylcyclohexyl)carbonyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044509-21-8 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-5-[[[4-methoxy-2-pyridinyl]amino]methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-(2,4,6-trimethylbenzoyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044509-22-9 CAPLUS

CN L-Alanine, N-[(phenylmethyl)sulfonyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044509-31-0 CAPLUS

CN L-Alanine, N-benzoyl-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044513-28-1 CAPLUS

CN L-Alanine, N-(2-phenylacetyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044513-33-8 CAPLUS

CN L-Alanine, N-([1,1'-biphenyl]-4-ylcarbonyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044513-36-1 CAPLUS

CN L-Alanine, N-(1-oxo-3-phenylpropyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044513-39-4 CAPLUS

CN L-Alanine, N-[(butylamino)carbonyl]-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044513-41-8 CAPLUS

CN L-Alanine, N-[(phenylamino)carbonyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044513-92-9 CAPLUS

CN L-Alanine, N-[[[(phenylmethyl)amino]carbonyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044514-38-6 CAPLUS

CN L-Alanine, N-[[[(2,6-dimethylphenyl)amino]carbonyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044514-86-4 CAPLUS

CN L-Alanine, N-[[[(2-phenylethyl)amino]carbonyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044515-32-3 CAPLUS

CN L-Alanine, N-[[[1,1'-biphenyl]-4-ylamino]carbonyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044515-50-5 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[2-(trifluoromethyl)benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.

10/593,801




RN 1044515-52-7 CAPLUS
CN L-Alanine, 3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[3-(trifluoromethyl)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1044515-53-8 CAPLUS
CN L-Alanine, 3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[4-(trifluoromethyl)benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044515-55-0 CAPLUS
CN L-Alanine, N-[3,5-bis(trifluoromethyl)benzoyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.

10/593,801




RN 1044515-58-3 CAPLUS
CN L-Alanine, N-(2-methylbenzoyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1044515-60-7 CAPLUS
CN L-Alanine, N-(2-methoxybenzoyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044515-61-8 CAPLUS
CN L-Alanine, N-(4-methylbenzoyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044515-63-0 CAPLUS

CN L-Alanine, N-(2,6-dimethoxybenzoyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044515-66-3 CAPLUS

CN L-Alanine, N-(cyclohexylcarbonyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044515-68-5 CAPLUS

CN L-Alanine, N-(2,6-dimethylbenzoyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044515-77-6 CAPLUS

CN L-Alanine, N-(3,5-dimethylbenzoyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044515-78-7 CAPLUS

CN L-Alanine, 3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-(3,4,5-trimethoxybenzoyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044515-84-5 CAPLUS

CN L-Alanine, N-(2-fluorobenzoyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

10/593,801


Absolute stereochemistry.



RN 1044515-85-6 CAPLUS

CN L-Alanine, N-(2-nitrobenzoyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044515-86-7 CAPLUS

CN L-Alanine, N-(2-chlorobenzoyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044516-09-7 CAPLUS

CN L-Alanine, N-(2,6-dichlorobenzoyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044516-11-1 CAPLUS

CN L-Alanine, N-(2,6-difluorobenzoyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044516-13-3 CAPLUS

CN L-Alanine, N-[(3-methyl-2-thienyl)carbonyl]-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044516-63-3 CAPLUS

CN L-Alanine, N-(3-methyl-1-oxo-2-phenylbutyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044516-65-5 CAPLUS

CN L-Alanine, N-(2-ethylbenzoyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044516-67-7 CAPLUS

CN L-Alanine, N-([1,1'-biphenyl]-2-ylcarbonyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044516-80-4 CAPLUS

CN L-Alanine, N-[(2-methylcyclohexyl)carbonyl]-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.

10/593,801




RN 1044516-81-5 CAPLUS
CN L-Alanine, N-[(1-phenylcyclopropyl)carbonyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1044516-82-6 CAPLUS
CN L-Alanine, N-[(1-phenylcyclopentyl)carbonyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044516-84-8 CAPLUS
CN L-Alanine, N-(2,2-dicyclohexylacetyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044516-90-6 CAPLUS

CN L-Alanine, N-[2-(dimethylamino)benzoyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044516-92-8 CAPLUS

CN L-Alanine, N-[2-[(difluoromethyl)thio]benzoyl]-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044517-00-1 CAPLUS

CN L-Alanine, N-(2-methyl-1-oxopentyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044517-06-7 CAPLUS

CN L-Alanine, N-(3-cyclopentyl-1-oxopropyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044517-07-8 CAPLUS

CN L-Alanine, N-(cyclobutylcarbonyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044517-13-6 CAPLUS

CN L-Alanine, N-(3,3-dimethyl-1-oxobutyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044517-15-8 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-(3,5,5-trimethyl-1-oxohexyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044517-18-1 CAPLUS

CN L-Alanine, N-(1-oxopropyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044517-20-5 CAPLUS

CN L-Alanine, N-(2,2-dimethyl-1-oxopropyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.

10/593,801




RN 1044517-21-6 CAPLUS
CN L-Alanine, N-(2,2-dimethyl-1-oxobutyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1044517-37-4 CAPLUS
CN L-Alanine, N-(cyclopropylcarbonyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044517-40-9 CAPLUS
CN L-Alanine, N-(2-cyclopentylacetyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044517-44-3 CAPLUS

CN L-Alanine, N-(2-methyl-1-oxopropyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044517-45-4 CAPLUS

CN L-Alanine, N-(2-cyclohexylacetyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044517-53-4 CAPLUS

CN L-Alanine, N-(1-oxo-2-propylpentyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044517-56-7 CAPLUS

CN L-Alanine, N-(4-methyl-1-oxopentyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044517-62-5 CAPLUS

CN L-Alanine, N-(2-cycloheptylacetyl)-3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044517-63-6 CAPLUS

CN L-Alanine, 3-[[2-[[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]-N-[2,4,6-tris(1-methylethyl)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1044517-64-7 CAPLUS

CN L-Alanine, N-(1-oxo-4-phenylbutyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1044517-84-1 CAPLUS

CN L-Alanine, N-(1-oxo-5-phenylpentyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1146947-94-5 CAPLUS

CN L-Alanine, N-(butylsulfonyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


10/593,801



RN 1146950-65-3 CAPLUS

CN L-Alanine, N-(methylsulfonyl)-3-[[2-[[(3R,5S)-5-[(2-pyridinylamino)methyl]-3-pyrrolidinyl]oxy]acetyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>